Floatz logo

Atezolizumab

Hepatic Portal Vein Tumor Invasion

Third Affiliated Hospital, Sun Yat-Sen Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Hepatic Portal Vein Tumor Invasion cohort.

Asset / SponsorPhaseRating
Sorafenib
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LENVATINIB
First Hospital of China Medical University
Phase 4BBB
WARFARIN
Kafrelsheikh University
Phase 4BB
NADROPARIN
Shanghai Zhongshan Hospital
Phase 4BB
Enoxaparin
Institute of Liver and Biliary Sciences, India
Phase 4BB

View all 27 →

Same molecule, other indications

Atezolizumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Stage IV Lung Cancer AJCC v8Dormant
BB
Indicative ·
70 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →